N-methanocarbathymidine ((
N)-MCT), a
thymidine analog incorporating a
pseudosugar with a fixed Northern conformation, exhibits potent antiherpetic activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). This study contrasts the metabolic pathway of (
N)-MCT and the well-known antiherpetic agent
ganciclovir (GCV) in HSV-1-infected and uninfected Vero cells. Treatment of HSV-1 infected Vero cells immediately after
viral infection with (
N)-MCT profoundly inhibited the development of HSV-1
infection. Using standard plaque reduction assay to measure
viral infection, (
N)-MCT showed a potency greater than that of
ganciclovir (GCV), the IC50s were 0.02 and 0.25 microM for (
N)-MCT and GCV, respectively. (
N)-MCT showed no cytotoxic effect on uninfected Vero cells (CC50>100 microM). Dose and time dependence studies showed high levels of (
N)-MCT-
triphosphate ((
N)-MCT-TP), and GCV-
triphosphate (GCV-TP) in HSV-1-infected cells incubated with (
N)-MCT or GCV, respectively. In contrast, uninfected cells incubated with (
N)-MCT showed elevated levels of (
N)-MCT-monophosphate only, while low levels of mono, di- and triphosphates of GCV were found following incubation with GCV. Although the accumulation rate of (
N)-MCT and GCV
phosphates in HSV-1-infected cells were similar, the decay rate of (
N)-MCT-TP was slower than that of GCV-TP. These results suggest that: (1) the
antiviral activity of (
N)-MCT against herpes viruses is mediated through its
triphosphate metabolite; (2) in contrast to GCV, the diphosphorylation of (
N)-MCT in HSV-1- infected cells is the rate limiting step; (3) (
N)-MCT-TP accumulates rapidly and has a long half-life in HSV-1-infected cells; and (4) HSV-tk catalyzed the mono, and diphosphorylation of (
N)-MCT while monophosphorylating GCV only. These results provide a biochemical rational for the highly selective and effective inhibition of HSV-1 by (
N)-MCT.